Publish date:

Jim Cramer's Stop Trading! Buy Amgen

Cramer also likes Celgene.



(AMGN) - Get Amgen Inc. Report

, Jim Cramer said Thursday on CNBC's Stop Trading! segment.

Cramer said he'd like to know more about the big biotech's drug pipeline, and the fact that management has been mum on the subject makes him "nervous." Even so he believes the risk is 3 points down and the potential reward is 7 points up.

Cramer said Amgen rival


(CELG) - Get Celgene Corporation Report

also presents an attractive risk-reward balance now.

Cramer said he'd steer clear of

J.P. Morgan

(JPM) - Get JPMorgan Chase & Co. (JPM) Report

because of big writedowns possibly just around the corner. Cramer would rather own


TheStreet Recommends

(CAT) - Get Caterpillar Inc. Report

even though the stock hasn't "acted as well" as rivals such as


(DE) - Get Deere & Company Report


At the time of publication, Cramer was long Caterpillar.

Jim Cramer is a director and co-founder of He contributes daily market commentary for's sites and serves as an adviser to the company's CEO. Outside contributing columnists for and, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for

Action Alerts PLUS. Watch Cramer on "Mad Money" weeknights on CNBC. Click

here to order Cramer's latest book, "Mad Money: Watch TV, Get Rich," click

here to order his book, "Real Money: Sane Investing in an Insane World," click

here to get his second book, "You Got Screwed!" and click

here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by

clicking here. has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from